Savara, Inc. - Common Stock (SVRA)
2.7900
0.00 (0.00%)
Savara Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for rare respiratory diseases
The company is dedicated to improving the lives of patients with unmet medical needs by harnessing its expertise in inhalation therapy and drug delivery. Savara's ambitious pipeline includes candidates aimed at addressing conditions such as pulmonary diseases, and its research is driven by a commitment to scientific excellence and patient outcomes. Through collaboration and cutting-edge technology, Savara strives to bring new and effective therapies to market, ultimately enhancing the quality of life for those affected by respiratory ailments.
![](https://cdn.benzinga.com/files/images/story/2024/09/09/Movers_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · September 9, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
SVRA stock results show that Savara missed analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 12, 2024
![](https://cdn.benzinga.com/files/images/story/2024/06/26/bz-pharma-briefs.jpeg?width=1200&height=800&fit=crop)
Savara announces Phase 3 IMPALA-2 trial results for molgramostim in treating autoimmune pulmonary alveolar proteinosis. The inhaled GM-CSF met primary and secondary endpoints, showing significant improvements.
Via Benzinga · June 26, 2024
![](https://investorplace.com/wp-content/uploads/2021/04/wall-street-stock-market.jpg)
It's time to dive into the biggest pre-market stock movers as we check out all of the latest news happening on Wednesday morning!
Via InvestorPlace · June 26, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
SVRA stock results show that Savara missed analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 9, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
SVRA stock results show that Savara beat analyst estimates for earnings per share the fourth quarter of 2023.
Via InvestorPlace · March 7, 2024
![](https://g.foolcdn.com/editorial/images/718331/novartisandmeridian.jpg)
The clinical-stage biopharmaceutical company focuses on therapies to treat rare respiratory diseases.
Via The Motley Fool · January 27, 2023
![](https://investorplace.com/wp-content/uploads/2019/07/penny-stocks-words.jpg)
These three penny stocks to buy are poised for major upside over the medium-term, for various reasons worth exploring.
Via InvestorPlace · June 19, 2024
![](https://investorplace.com/wp-content/uploads/2022/03/penny-stocks-1024x576.png)
Don’t miss out on these three penny stocks, which have amazing potential to take off following upcoming business developments this year.
Via InvestorPlace · June 11, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 16, 2024
![](https://cdn.benzinga.com/files/images/story/2024/01/02/image_3.jpg?width=1200&height=800&fit=crop)
U.S. stocks traded mostly lower, with the Nasdaq Composite falling around 200 points on Tuesday.
Via Benzinga · January 2, 2024
![](https://cdn.benzinga.com/files/images/story/2023/Coforge-share-price.jpeg?width=1200&height=800&fit=crop)
Investors who are ready to dive into the OTC pool have more options than ever, both with the number of stocks to choose from and available investing platforms.
Via Benzinga · November 8, 2023
![](https://investorplace.com/wp-content/uploads/2021/12/penny-stocks-1600.jpg)
Consider three intriguing penny stocks for investors looking to add a bit more risk to their portfolio in times like these.
Via InvestorPlace · September 27, 2023
![](https://investorplace.com/wp-content/uploads/2022/03/penny-stocks-1024x576.png)
When all the focus lies on the largest names of the economy, these best penny stocks to buy offer a great risk/reward ratio.
Via InvestorPlace · September 12, 2023
![](https://cdn.benzinga.com/files/images/story/2023/07/20/johnson__johnson_-_logo_0.jpg?width=1200&height=800&fit=crop)
U.S. stocks traded mixed, with the Dow Jones gaining over 200 points on Thursday. Here are some big stocks recording gains in today’s session. Tarsus Pharmaceuticals, Inc. (NASDAQTARS) shares rose 12.3% to $22.59.
Via Benzinga · July 20, 2023
![](https://cdn.benzinga.com/files/images/story/2023/06/30/carnival-logo.jpg?width=1200&height=800&fit=crop)
U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording gains in today’s session.
Via Benzinga · June 30, 2023
![](https://cdn.benzinga.com/files/images/story/2023/05/30/barnwell_industries_-_logo.jpg?width=1200&height=800&fit=crop)
The Dow Jones closed higher by over 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Via Benzinga · May 30, 2023
![](https://g.foolcdn.com/editorial/images/732720/healthcare-lab-treatment-research-scientist-1.jpg)
The company released first-quarter earnings and said it had completed a phase 3 trial enrollment for its lead therapy.
Via The Motley Fool · May 16, 2023
![](/next-assets/images/schema-image-default.png)
Via Benzinga · April 3, 2023
![](https://cdn.benzinga.com/files/images/story/2023/02/21/image13.jpg?width=1200&height=800&fit=crop)
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via Benzinga · February 21, 2023
![](https://cdn.benzinga.com/files/images/story/2023/01/04/image14.jpg?width=1200&height=800&fit=crop)
The Dow Jones edged lower on the first trading session of 2023. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Via Benzinga · January 4, 2023
![](https://cdn.benzinga.com/files/images/story/2022/earnings_image_780.png?width=1200&height=800&fit=crop)
Savara (NASDAQSVRA) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Savara reported in-line EPS of $-0.06 versus an estimate of $-0.06.
Via Benzinga · August 11, 2022
![](https://cdn.benzinga.com/files/images/story/2022/movers_image_10430.jpeg?width=1200&height=800&fit=crop)
Gainers
Via Benzinga · June 13, 2022
![](https://cdn.benzinga.com/files/images/story/2022/earnings_image_6375.jpeg?width=1200&height=800&fit=crop)
Savara (NASDAQSVRA) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Savara beat estimated earnings by 28.57%, reporting an EPS of $-0.05 versus an estimate of $-0.07.
Via Benzinga · May 11, 2022
![](https://cdn.benzinga.com/files/images/story/2022/04/22/lab-5740505_1920.jpg?width=1200&height=800&fit=crop)
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via Benzinga · April 22, 2022